ABBV stock verdict - Avoid
ABBV
AbbVie Inc.
AVOIDHealthcare
$264.34
Fundamentals below bar
$264.34
Heavy$141.46Buy$188.61Fair$235.76Exit$282.91
VALUE47
GROWTH27
QUALITY100
TECHNICAL—
TRUST SCORE
96High
confidence in this read — data completeness, earnings quality & coverage
Technicals: insufficient price history
PROS
- Balance sheet holds net cash (cash exceeds total debt)
- Converts 28% of revenue into free cash flow
- High gross margin of 68% (3-yr avg)
CONS
- Expensive on trailing earnings (P/E 74.0×)
- Company has a low return on equity of -106.3% (TTM)
- TTM EPS fell 1.3% year-over-year
✳ Pros and cons are machine-generated from the latest fundamentals and technicals.
EARNINGS QUALITY · we check the accounting so you don't have to
✓Operating cash flow is 309% of net income — profit is backed by real cash
Analysis as of 2026-09-25 · price live, fundamentals from latest filings
Congress Trading — last 90 days
See what senators are buying and selling on ABBV. Sign in to unlock.
📊 Options Flow — Put/Call Ratio
FAQ
Why is ABBV rated Avoid?
ABBV (AbbVie Inc.) is rated Avoid because the model combines fundamentals, price action, and earnings-quality checks. The current signal is Fundamentals below bar. Balance sheet holds net cash (cash exceeds total debt) and Converts 28% of revenue into free cash flow
Is ABBV overvalued right now?
ABBV is trading at $264.34 versus an estimated fair value of $235.76. That puts the stock in avoid territory on this framework. Expensive on trailing earnings (P/E 74.0×) and Company has a low return on equity of -106.3% (TTM)
What should I watch before acting on ABBV?
Watch the trust score of 96, the earnings-quality checks, and any red flags. Expensive on trailing earnings (P/E 74.0×) and Company has a low return on equity of -106.3% (TTM)